Henatinib Maleate

马来酸海那替尼

Report date: 2022/07/19 16:22:54
NME

Base Information

Drug NameHenatinib Maleate
Drug Alias NameHena
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionVascular endothelial growth factor receptor 2 antagonists
TargetsVascular endothelial growth factor receptor 2
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaDiscontinued
Originator CompaniesJiangsu Hengrui Medicine Co LtdJiangsu Hansoh Pharmaceutical Group Co LtdChina State Institute of Pharmaceutical Industry Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesN/A
Inactive CompaniesJiangsu Hengrui Medicine Co Ltd
Active IndicationsN/A
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A